ストックスクリーナーアプリを入手
1.32
3.65%
-0.05
アフターアワーズ：
1.32
Cue Biopharma Inc (CUE) 最新ニュース
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
HPV+ Recurrent/Metastatic Head and Neck Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE) - ACCESS Newswire
Pancreatic Adenocarcinoma Market Growth Projections - openPR
Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update - MarketBeat
Artiva Biotherapeutics expands board with industry veteran - MSN
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - The Manila Times
Artiva Biotherapeutics appoints new director and committee members - MSN
Artiva Biotherapeutics appoints new director and committee members By Investing.com - Investing.com Nigeria
Artiva expands Board with appointment of Dan Baker, M.D - TipRanks
Former J&J Drug Development Chief Who Created Multi-Billion Dollar Therapies Joins Rising Biotech Board - StockTitan
Geode Capital Management LLC Increases Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Geode Capital Management LLC Purchases 212,394 Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) - Defense World
HPV16+ Cancer Clinical and Non-Clinical Studies, Key - openPR
Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Up 8.0% in December - MarketBeat
Cue Biopharma (NASDAQ:CUE) versus FibroGen (NASDAQ:FGEN) Head-To-Head Comparison - Defense World
The definitive Boston biotech layoff tracker for 2024 - The Business Journals
Certain Common Stock of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2024. - Marketscreener.com
Cue Biopharma CEO Daniel Passeri buys $30,900 in stock By Investing.com - Investing.com Australia
Cue Biopharma CEO Daniel Passeri buys $30,900 in stock - Investing.com India
Insider Buying: Daniel Passeri Acquires 30,000 Shares of Cue Bio - GuruFocus.com
Cue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in Stock - MarketBeat
Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5% - MarketBeat
Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus sparks debate - Investing.com Australia
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Cue Biopharma Grants 200,000 Share Option Award to New Development Chief - StockTitan
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Strong week for Cue Biopharma (NASDAQ:CUE) shareholders doesn't alleviate pain of five-year loss - Simply Wall St
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Cue Biopharma CEO to Present Clinical Updates at Piper Sandler Healthcare Conference | CUE Stock News - StockTitan
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates - MSN
Cue Biopharma, Inc. (NASDAQ:CUE) Shares Purchased by GSA Capital Partners LLP - Defense World
The Escalator: Pfizer, Eli Lilly, CVS Health and more - MM+M Online
Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Cue Biopharma’s Nasdaq Compliance Struggle: Risks and Implications for Future Stability - MSN
Jefferies cuts Cue Biopharma shares target, retains buy rating on potential - Investing.com UK
Cue Biopharma earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Cue Biopharma Inc (CUE) Quarterly 10-Q Report - Quartzy
Cue names Daniel Baker interim CDO, CSO Anish Suri to transition to advisor role - MSN
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Cue Biopharma Reports Increased Revenue Amid Ongoing Losses - TipRanks
Cue Biopharma Inc (CUE) Q3 2024 Earnings: EPS of $0.17 Beats Est - GuruFocus.com
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):